Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. China
  4. Shanghai Stock Exchange
  5. Shanghai Fosun Pharmaceutical (Group) Co., Ltd.
  6. Summary
    600196   CNE000000X38

SHANGHAI FOSUN PHARMACEUTICAL (GROUP) CO., LTD.

(600196)
  Report
 SummaryChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   End-of-day quote. End-of-day quote Shanghai Stock Exchange
06/17/2021 06/18/2021 06/21/2021 06/22/2021 06/23/2021 Date
62.25 62.7 63 67.23 68.41 Last
29130420 26854060 28941200 69604170 65853700 Volume
+1.80% +0.72% +0.48% +6.71% +1.76% Change
Estimated financial data (e)
Sales 2021 41 153 M 6 350 M 6 350 M
Net income 2021 4 327 M 668 M 668 M
Net Debt 2021 16 835 M 2 598 M 2 598 M
P/E ratio 2021 40,8x
Yield 2021 0,73%
Sales 2022 45 289 M 6 988 M 6 988 M
Net income 2022 5 227 M 807 M 807 M
Net Debt 2022 19 701 M 3 040 M 3 040 M
P/E ratio 2022 33,1x
Yield 2022 0,92%
Capitalization 138 B 21 249 M 21 228 M
EV / Sales 2021 3,75x
EV / Sales 2022 3,47x
Nbr of Employees 32 258
Free-Float 58,8%
More Financials
Company
Shanghai Fosun Pharmaceutical (Group) Co., Ltd. is a China-based company, principally engaged in the research and development, production and distribution of pharmaceuticals. The Company's products are mainly applied in the treatment of metabolism and digestive tract system, cardiovascular system, central nervous system, blood system, anti-tumor and anti-infection diseases. The Company is also engaged in medical... 
Sector
Pharmaceuticals
Calendar
08/31Earnings Release
More about the company
Ratings of Shanghai Fosun Pharmaceutical (Group) Co., Ltd.
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
B+
More Ratings
All news about SHANGHAI FOSUN PHARMACEUTICAL (GROUP) CO., LTD.
06/23SHANGHAI FOSUN PHARMACEUTICAL  : Fosun Pharma JV Secures CAR T-Cell Therapy Appr..
MT
06/22Taiwan Buddhist group enters fray for BioNTech COVID vaccines
RE
06/22SHANGHAI FOSUN PHARMACEUTICAL  : Fosun Pharma Wins Nod to Market Lymphoma Drug i..
MT
06/22SHANGHAI FOSUN PHARMACEUTICAL  : Chinese regulator approves first CAR-T cell the..
RE
06/22SHANGHAI FOSUN PHARMACEUTICAL  : Overseas regulatory announcement (h shares)
PU
06/22SHANGHAI FOSUN PHARMACEUTICAL  : Notice of the 2021 second extraordinary general..
PU
06/22SHANGHAI FOSUN PHARMACEUTICAL  : Proxy Forms
PU
06/22SHANGHAI FOSUN PHARMACEUTICAL  : Report on the use of proceeds previously raised..
PU
06/18SHANGHAI FOSUN PHARMACEUTICAL  : Overseas regulatory announcement (h shares)
PU
06/18Taiwan to allow Foxconn's Gou, TSMC to negotiate for vaccines
RE
06/17REFILE-Foxconn founder asks Taiwan to allow vaccine talks with Chinese firm
RE
06/15Chinese Shares Extend Losses; Fosun Pharma Slides 7% on Vaccine Update
MT
06/15MARKET CHATTER : Fosun Pharma to Kick Off Production of BioNTech Vaccines in Aug..
MT
06/13SHANGHAI FOSUN PHARMACEUTICAL  : Fosun Cancer Drug Approved for Clinical Trial
MT
06/11SHANGHAI FOSUN PHARMACEUTICAL  : Poll results of the resolutions proposed at the..
PU
More news
News in other languages on SHANGHAI FOSUN PHARMACEUTICAL (GROUP) CO., LTD.
05/06MÄRKTE ASIEN/Tokio sehr fest - Chin. Impfstoffhersteller stürzen ab
05/06MÄRKTE ASIEN/Japan sehr fest - Konflikt mit China belastet Sydney
04/28EXENCIONES DE PROPIEDAD INTELECTUAL : BioNTech
03/24Hongkong stoppt Pfizer/BioNTech-Impfstoff wegen fehlerhafter Verpackung
03/23Coronavirus-Hong Kong suspend temporairement l'utilisation du vaccin Pfizer/B..
More news
Analyst Recommendations on SHANGHAI FOSUN PHARMACEUTICAL (GROUP) CO., LTD.
More recommendations
Chart SHANGHAI FOSUN PHARMACEUTICAL (GROUP) CO., LTD.
Duration : Period :
Shanghai Fosun Pharmaceutical (Group) Co., Ltd. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends SHANGHAI FOSUN PHARMACEUTICAL (GROUP) CO., LTD.
Short TermMid-TermLong Term
TrendsNeutralBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 9
Last Close Price 68,41 CNY
Average target price 52,62 CNY
Spread / Average Target -23,1%
EPS Revisions
Managers and Directors
NameTitle
Xiao Hui Guan Executive President & Chief Financial Officer
Yu Qing Chen Co-President
Ke Xin Wang Co-President
Dong Ming Li Co-President
Yi Fang Wu Chairman
Sector and Competitors